Magnesium Sulfate in Pregnancy: Primary Indications
Magnesium sulfate in pregnancy is primarily used for three evidence-based indications: prevention and treatment of eclamptic seizures in preeclampsia/eclampsia, fetal neuroprotection before anticipated very preterm birth (<32 weeks), and short-term tocolysis (up to 48 hours) to allow corticosteroid administration.
Core Clinical Indications
1. Eclampsia Prevention and Treatment (Strongest Indication)
Magnesium sulfate approximately halves the rate of eclamptic seizures, with about 100 women needing treatment to prevent one seizure 1. This represents the most robust evidence base for magnesium use in pregnancy.
Dosing Protocol for Preeclampsia/Eclampsia:
- Loading dose: 4-5 g IV over 5-15 minutes 2
- Maintenance: 1 g/hour continuous infusion for 24 hours 2
- Alternative regimen: After IV loading, 4-5 g IM into alternate buttocks every 4 hours 3
- Recurrent seizures: Additional 2-4 g IV over 5-15 minutes 2
When to Administer:
The 2024 WHO guidelines 2 and 2018 ISSHP guidelines 1 recommend magnesium sulfate for:
- All women with eclampsia (active seizures)
- Severe preeclampsia with BP ≥160/110 mmHg
- Preeclampsia with severe features: severe headache, visual disturbances, epigastric pain, oliguria, pulmonary edema, elevated liver enzymes, or thrombocytopenia 2, 4
Important nuance: In low- and middle-income countries, all preeclamptic women should receive magnesium sulfate due to favorable cost-benefit ratio. In high-resource settings, selective use based on severity markers is reasonable 1.
Duration Controversy:
Standard practice continues magnesium for 24 hours postpartum 1. While one Latin American study suggested no benefit beyond 8g pre-delivery, this requires validation in other populations before changing practice 1.
2. Fetal Neuroprotection Before Preterm Birth
Magnesium sulfate reduces cerebral palsy risk by 40% (RR 0.60) and substantial gross motor dysfunction by 40% (RR 0.60) when given before very preterm birth 5.
Gestational Age Windows:
- Strongly recommended: 24+0 to 29+6 weeks 6
- Should be considered: 30+0 to 33+6 weeks 6
- May be discussed: 23+0 to 23+6 weeks 6
The 2024 UK guideline 6 extends consideration to 33+6 weeks for growth-restricted fetuses given evidence of neurological abnormalities persisting into the late preterm period.
Dosing for Neuroprotection:
Same loading and maintenance regimen as eclampsia prophylaxis: 4 g IV loading, then 1 g/hour maintenance 5.
3. Short-Term Tocolysis (Limited Role)
Magnesium sulfate may be used for up to 48 hours to delay delivery for corticosteroid administration, but NOT for prolonged tocolysis 7. Evidence shows it is ineffective for preventing preterm birth and high cumulative doses may increase infant mortality 8.
The FDA changed magnesium from Category A to Category D specifically because of inappropriate prolonged use (>5-7 days) for tocolysis 3, 7.
Critical Safety Monitoring
Toxicity Surveillance:
Monitor for magnesium toxicity by checking 2:
- Patellar reflexes (absent reflexes = early toxicity)
- Respiratory rate (bradypnea <12/min = concerning)
- Urine output (oliguria increases toxicity risk)
Serum magnesium levels are NOT routinely needed unless toxicity is suspected or renal impairment exists 2. Therapeutic range for seizure control is 4-8 mEq/L (approximately 6 mg/100 mL) 3.
Contraindications and Precautions:
- Maximum dose: 30-40 g per 24 hours in normal renal function 3
- Renal insufficiency: Maximum 20 g per 48 hours with frequent serum monitoring 3
- Duration limit: Do NOT exceed 5-7 days continuous use due to fetal bone toxicity risk 3
Fetal Risks with Prolonged Use:
Continuous administration beyond 5-7 days causes fetal hypocalcemia, skeletal demineralization, osteopenia, and neonatal fractures 3. This is why prolonged tocolysis is contraindicated.
Concurrent Management
Fluid Restriction:
Limit IV fluids to 60-80 mL/hour to prevent pulmonary edema in preeclamptic women 1, 2, 1. Preeclamptic women have capillary leak and are at high risk for fluid overload.
Blood Pressure Control:
Magnesium sulfate is NOT an antihypertensive. Treat severe hypertension (≥160/110 mmHg) separately with:
- Labetalol (10-20 mg IV) OR
- Nifedipine (5-10 mg PO) OR
- Hydralazine (5 mg IV) 2
Timing of Delivery:
Delivery remains the definitive treatment for preeclampsia with severe features 9. Magnesium sulfate stabilizes the patient but does not cure the underlying disease. Expedite delivery once the woman is stable, particularly if eclampsia has occurred or severe features persist 2.
Common Pitfalls to Avoid
- Do NOT use magnesium sulfate for prolonged tocolysis (>48 hours) - this causes fetal harm 3, 7
- Do NOT forget fluid restriction - preeclamptic women need only 60-80 mL/hour 1
- Do NOT rely solely on serum levels - clinical monitoring (reflexes, respirations) is primary 2
- Do NOT delay delivery in severe preeclampsia once stabilized - magnesium is temporizing, not curative 9
- Do NOT withhold neuroprotection at 30-33 weeks - consider administration in this window, especially for growth restriction 6